Thu, 29th Jul 2021 07:10
July 29 (Reuters) - AstraZeneca's COVID-19 vaccine
sales more than tripled to $894 million in the second quarter
from the previous three months but shaved off 1 U.S. cent from
earnings, and the drugmaker updated its 2021 forecasts on
Thursday to include sales from its Alexion unit.
(Reporting by Pushkala Aripaka in Bengaluru and Alistair Smout
in London)
(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump...
(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth readi...
(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover ta...
Q1 revenue up 19% to $12.68 bln *
(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the ...
Astrazeneca (AZN)